Author

V. Guadalupi

h-index 19 View on Semantic Scholar

We have 3 of 92 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Lynch syndrome–associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort

Lynch syndrome–associated urothelial carcinoma (LS-UC) is a rare and undercharacterized clinical entity. While FGFR3 alterations are well described in sporadic urothelial carcinoma, their prevalence and clinical implications in LS-UC remain unclear. We aimed to provide a comprehensive clinical and molecular characteriz...

A. Rametta, M. Barella, A. Scardino et al. · Familial Cancer · 0 citations

Open access Sep 2026

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma.

BACKGROUND Cohort 1 of the phase III THOR trial met the primary endpoint of significantly longer overall survival (OS) with erdafitinib versus chemotherapy in patients with metastatic urothelial carcinoma (mUC) and select FGFR3/2 alterations who have progressed after prior anti-PD-(L)1 treatment. We present efficacy an...

Y. Loriot, N. Matsubara, S. H. Park et al. · ESMO Open · 0 citations

Open access Aug 2026

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

A model using simple, routine parameters and PSA doubling time can identify those at minimal risk of reclassification, enabling a safe reduction in biopsy intensity, and advocates for a risk-adaptive AS protocol.

C. Marenghi, F. Badenchini, B. Avuzzi et al. · Tumori · 0 citations